Mycotopia Therapies Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021
Mycotopia Therapies Issues CEO Letter to Stockholders, Reports on Significant Progress and Outlook for 2021
Mycotopia Therapies looking to unlock the full potential of psychedelic-derived medicines; Create Active Pharmaceutical Ingredient (API) for magic mushroom
尋求釋放迷幻衍生藥物的全部潛力的黴菌療法；為神奇蘑菇創造活性藥物成分(API)
MIAMI, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc., (OTC Pink: TPIA) (the "Company"), announced today that Ben Kaplan, President, Chief Executive Officer and Chairman, has issued a letter to Mycotopia Therapies' stockholders. The full text is as follows:
邁阿密，2021年11月4日(環球通訊社)--Mycotopia Treatment Inc.(場外交易代碼：TPIA)(以下簡稱“公司”)今天宣佈，該公司總裁、首席執行官兼董事長本·卡普蘭已經向Mycotopia Treatures的股東發出了一封信。全文如下：
To My Fellow Stockholders,
致我的股東們，
Over the course of 2021, Mycotopia Therapies has made significant progress in advancing our strategic plan and hit several key milestones in our journey. From a corporate standpoint, we are a fully reporting company with the SEC and have completed a name and symbol change to better reflect our company. We have also secured DTC eligibility by The Depository Trust Company ("DTC") for electronic settlement and transfer of our common shares in the United States, in an effort to enhance shareholder liquidity.
在2021年的歷程中，黴菌療法在推進我們的戰略計劃方面取得了重大進展，並達到了我們征程中的幾個關鍵里程碑。從企業的角度來看，我們是一家全面報道美國證券交易委員會的公司，為了更好地反映我們的公司，我們已經完成了名稱和符號的更改。我們還獲得了存託信託公司(“DTC”)的DTC資格，可以在美國以電子方式結算和轉讓我們的普通股，以努力提高股東的流動資金。
With these basic changes to the public company side of Mycotopia Therapies, we are now moving forward as a biopharma company focused on the discovery and early development of novel drug candidates, structurally related to the classic psychedelics but with vastly improved pharmaceutical characteristics and commercial potential.
隨着Mycotopia療法上市公司方面的這些基本變化，我們現在正在向前邁進，成為一家專注於發現和早期開發新藥候選藥物的生物製藥公司，這些候選藥物在結構上與經典迷幻藥相關，但具有極大改進的藥學特性和商業潛力。
Mycotopia Therapies recently entered into a supply agreement with Havn Life Sciences (CSE: HAVN) (OTC Pink: HAVLF). The terms of the agreement call for Havn Life Sciences to supply Mycotopia Therapies with naturally-derived psilocybin. Under the terms of the agreement, Mycotopia Therapies is classified as a specialty pharmaceutical company focused on the research, development, and commercialization of novel therapeutics for unmet needs. The benefit of this Psilocybin Supply Agreement is that it enables Mycotopia Therapies to get to the distribution and revenue generation phase of our business plan much faster.
黴菌療法公司最近與哈文生命科學公司(CSE：HAVN)(場外粉色市場代碼：HAVLF)簽訂了一項供應協議。協議的條款要求哈文生命科學公司向真菌病療法提供天然提取的裸蓋菇素。根據協議條款，Mycotopia Treatures被歸類為一家專業製藥公司，專注於針對未得到滿足的需求的新型療法的研究、開發和商業化。這份裸蓋菇素供應協議的好處是，它使黴菌療法能夠更快地進入我們商業計劃的分銷和創收階段。
Mycotopia Therapies has signed an LOI with a major manufacturer encompassing the IP for a water-soluble tablet for all psychedelics. This will give our Company the ability to develop robust formulations by eliminating uncontrolled stability variables, while focusing solely on therapeutic performance and clinical outcome.
黴託邦療法公司已經與一家主要製造商簽署了一份意向書，其中包括一種適用於所有迷幻劑的水溶性片劑的知識產權。這將使我們公司有能力通過消除不可控的穩定性變量來開發強健的配方，同時只關注治療性能和臨牀結果。
In addition, Mycotopia Therapies entered into a separate LOI to license IP from a public company focused on mushroom and psychedelic opportunities. This licensing agreement will provide us with a process that is similar to those used by Compass, MindMed, and Atai, which allow any psychedelic and delivery into the human body.
此外，Mycotopia Treatures還簽訂了一份單獨的意向書，從一家專注於蘑菇和迷幻藥物機會的上市公司獲得知識產權許可。這份許可協議將為我們提供一個類似於Compass、MindMed和ATAI使用的過程，允許任何迷幻藥物和藥物進入人體。
Mycotopia Therapies is currently working with one of the largest cannabis labs in the Netherlands to develop psychedelics. In our partnership we intend to jointly apply to the to the government to license certain molecules to be used in psychedelics. Our counterpart in the Netherlands collaborates with scientists, universities, pharmacies and innovative companies to garner a complete and unrivalled understanding of psychedelics. An innovative and vertically integrated phyto-pharmaceutical company with 25-years' experience the company collaborates with leading scientists, pharmacists and doctors. Mycotopia Therapies will benefit from many years of activities in the fields of research, production and processing of both cannabinoids and psychedelics. We believe their years of knowledge and experience will result in high quality, safe and reliable products.
Mycotopia Treatures目前正在與荷蘭最大的大麻實驗室之一合作開發迷幻劑。在我們的夥伴關係中，我們打算共同向政府申請許可某些分子用於致幻劑。我們在荷蘭的同行與科學家、大學、藥店和創新公司合作，以獲得對迷幻藥物的全面和無與倫比的理解。該公司是一家創新的垂直整合的植物製藥公司，擁有25年的經驗，與領先的科學家、藥劑師和醫生合作。菌斑療法將受益於在大麻類藥物和迷幻劑的研究、生產和加工領域的多年活動。我們相信，他們多年的知識和經驗將造就高質量、安全可靠的產品。
Our future plans call for opening psylocibin and ketamine clinics in Jamaica. The clinics will be under the direction of a licensed clinical psychiatrist. Mental health is the national health crisis everyone should be concerned about, since rates of anxiety, depression and PTSD keep climbing. Mycotopia Therapies' psylocibin and ketamine clinic will be designed to make the most peaceful and serene setting possible to give patients an ideal situation for psychedelic therapies. The primary focus of each clinic will be to help patients heal and reclaim their life under the direction of a licensed clinical psychiatrist.
我們未來的計劃是在牙買加開設木犀草素和氯胺酮診所。診所將由有執照的臨牀精神科醫生指導。心理健康是每個人都應該關注的國家健康危機，因為焦慮、抑鬱和創傷後應激障礙的比例不斷攀升。黴菌治療公司的心理菌素和氯胺酮診所將設計成最和平、最寧靜的環境，為患者提供一個理想的迷幻治療環境。每個診所的主要重點將是幫助患者在有執照的臨牀精神病學家的指導下治癒和恢復他們的生活。
Psychedelics are currently being used during therapy to better understand the pathway to mental wellness. During psychedelic enhanced psychotherapy many patients find that situations from their past are uncovered. To be able to fully benefit from what surfaces, a structured approach is needed. With the assistance of a licensed clinical psychiatrist, these psychedelics experiences can help patients understand the thoughts and feelings they uncover. Jamaica's peaceful and serene setting and its relaxed life style make it a perfect place for a psychedelic enhanced psychotherapy.
目前，在治療過程中使用迷幻劑是為了更好地理解心理健康的途徑。在迷幻強化心理治療期間，許多患者發現他們過去的情況被揭露了。為了能夠充分受益於什麼表面，需要一種結構化的方法。在有執照的臨牀精神病學家的幫助下，這些迷幻體驗可以幫助患者理解他們揭示的想法和感受。牙買加寧靜的環境和輕鬆的生活方式使其成為迷幻強化心理治療的完美場所。
I believe psychedelic-based medicine has the potential to revolutionize the way we treat mental health issues. Mycotopia Therapies is committed to creating psychedelic-derived medicines that will better the lives of millions. We intend to recruit a world-class Board of Directors and Medical Advisory Board that has the expertise and passion necessary to not only achieve that objective, but to help us become a leader in the field.
我相信以迷幻藥為基礎的醫學有可能徹底改變我們治療精神健康問題的方式。Mycotopia Treatures致力於創造迷幻衍生藥物，這些藥物將改善數百萬人的生活。我們打算招募一個世界級的董事會和醫療顧問委員會，他們不僅擁有實現這一目標所需的專業知識和激情，而且還將幫助我們成為該領域的領先者。
I would like to thank you for your continued support along this journey and look forward to sharing more good news with you soon.
感謝大家一如既往的支持，期待着很快與大家分享更多的好消息。
About Mycotopia Therapies
關於菌斑療法
Mycotopia Therapies focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia Therapies can be found on the Company's website at: https://www.mycotopiatherapies.com.
黴菌治療專注於幫助你治癒和找回你的生活。你的康復之旅是通過迷幻增強型心理治療，結合心理健康從業者的專業團隊和尖端技術，瞭解心理健康的原因和工作。迷幻療法是一種整體的和靈性的治療方法，多年來已經顯示出成功的治療效果。有關黴菌療法的更多信息，請訪問公司網站：https://www.mycotopiatherapies.com.。
Forward-Looking Statement Disclaimer
前瞻性聲明免責聲明
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company's research, manufacturing and other development efforts; (ii) the Company's ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company's products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company's industry and introduction of competing products; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in 20/20 Global, Inc.'s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.
本新聞稿包含“1995年私人證券訴訟改革法案”所指的“前瞻性陳述”。此類聲明的前綴可能是“打算”、“可能”、“將”、“計劃”、“預期”、“預期”、“計劃”、“預測”、“估計”、“目標”、“相信”、“希望”、“潛在”或類似的詞語。前瞻性陳述基於某些假設，會受到各種已知和未知的風險和不確定性的影響，其中許多風險和不確定性是公司無法控制的，無法預測或量化，因此，實際結果可能與這些前瞻性陳述中明示或暗示的結果大不相同：(I)公司研究、製造和其他開發工作的發起、時間、進展和結果；(Ii)公司推進其產品成功完成開發和商業化的能力；(Iii)製造、開發、商業化的能力。, (4)缺乏足夠的資金為產品開發和業務運營提供資金；(5)公司所在行業內具有競爭力的公司和技術以及競爭產品的推出；(6)公司建立和維持公司合作的能力；(7)關鍵管理人員的流失；(8)公司能夠建立和維持涵蓋其產品的知識產權的保護範圍以及在不侵犯他人知識產權的情況下運營其業務的能力；(Ix)可能未能遵守適用的健康信息隱私和安全法律以及其他州和聯邦隱私和安全法律；以及(X)難以預測美國FDA及其法規的行動。本新聞稿中包含的所有前瞻性陳述僅在本新聞稿發佈之日作出。除非法律要求，否則公司不承擔更新任何書面或口頭前瞻性陳述的義務。有關公司和可能影響前瞻性陳述實現的風險因素的更詳細信息包含在20/20 Global，Inc.於2015年9月24日提交給美國證券交易委員會(SEC)的F-1表格註冊聲明(經修訂)中的“風險因素”標題下，該聲明可在SEC的網站http://www.sec.gov.上查閲。
Contact for 20/20 Global and Ehave
20/20全球和eHave的聯繫人
Media Inquiries: Gabe Rodriguez
媒體詢問：加布·羅德里格斯(Gabe Rodriguez)
Email: Gabe@Ehave.com
電子郵件：郵箱：gabe@ehave.com
Investor Relations:
投資者關係：
Email: Ir@Ehave.com
電子郵件：郵箱：ir@ehave.com
Phone: (623) 261-9046
電話：(623)261-9046
譯文內容由第三人軟體翻譯。